We are proud to announce that Dr. Nicholas Leeper has joined MONCYTE Health as Chair of the Board.
Dr. Nicholas Leeper is a Professor, Chief of Vascular Medicine, and Director of Vascular Research at Stanford University. A board-certified cardiologist, Dr. Leeper specializes in the care of patients with atherosclerotic cardiovascular diseases. He is actively engaged with the Society for Vascular Medicine (SVM), the Gordon Research Conferences (GRC), and the American Society for Clinical Investigation (ASCI) and has held multiple volunteer roles at the American Heart Association (AHA). Dr. Leeper leads a translationally oriented laboratory focused on leveraging human genetics and advanced immunology approaches to discover new cardiovascular therapeutics. He previously cofounded the immuno-oncology company, Forty Seven, Inc. (acquired by Gilead in 2020), and is currently a co-founder of Bitterroot Bio, a company focused on developing novel immunotherapies for cardiovascular disease.
“We are honored to welcome Dr. Nicholas Leeper to the MONCYTE Health team as Chair of the Board. His exceptional clinical expertise, translational leadership, and track record of building innovative companies will be instrumental as we advance MONCYTE Health’s mission to develop precision medicine applications to gain novel insight into inflammatory processes and residual cardiovascular risk”, said Tamara Alagirova, CEO and founder of MONCYTE Health.
Dr. Leeper earned a BA in chemistry and an MD from the University of Chicago. He completed his internal medicine training at the University of California, San Francisco (UCSF), before pursuing fellowships in cardiovascular disease and vascular medicine at Stanford University.
